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adjuvanted Q-antigen. At days 0, 21 and 42, sera were
tested for hemagglutination-inhibiting (HI) antibody against
A/Indonesia/5/2005 and A/Vietnam/1194/2004 (Clade 1).
Solicited local and general symptoms, unsolicited adverse
events (AEs) and serious adverse events (SAEs) were
recorded. (110028/NCT00510874).
Although injection site pain was more frequent in the AS-
adjuvanted vaccine groups, redness and swelling occurred
in <5% of subjects. General symptoms (day 0—6) were more
frequent in the AS vaccine groups but fever was uncommon
(≤2%). All AEs decreased after dose 2. Clinical laboratory
values and unsolicited AEs raised no safety concerns. No
vaccine-related SAEs occurred.
After dose 1, A/Indonesia seroconversion rates (SCR)
reached 42.1%—45.7% in the AS vaccine groups (con-
trol:6.7%). After dose 2, SCR and the percent of subjects
with HI titers ≥40 were 96.4%—97.2% in the AS vaccine
groups (control:17.3%). Homologous HI GMT was enhanced
≥44-fold in the pooled AS vaccine group. After 2 doses, SCR
to Clade 1A/Vietnam/1194/04 was 56.4%—62.1% for the AS
vaccine groups.
At an antigen-sparing dose, the AS-adjuvanted
A/Indonesia/05/2005 vaccines were markedly immunogenic
against the vaccine strain and a Clade 1 strain. Reacto-
genicity was increased but acceptable, and no other safety
concerns were identiﬁed.
doi:10.1016/j.ijid.2008.05.365
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Background: The lyophilized formulation of an oral, live
attenuated human rotavirus (RV) vaccine RIX4414 (Rotarix, a
trademark from GlaxoSmithKline) given concomitantly with
routine vaccines, has been shown to be highly immunogenic.
A phase II, randomised, double-blind, placebo-controlled
study (105722/NCT00345956) was conducted in Vietnam to
assess the immunogenicity, reactogenicity and safety of two
doses of RIX4414 oral suspension(liquid formulation) co-
administered in two different schedules with routine EPI
vaccines.
Methods: Healthy 6—10 week old infants(N = 375) were
enrolled and randomized into three groups to receive either
two doses of RIX4414 oral suspension (RIX4414-liq) and
one placebo(Pl) dose, according to a 0,1 month (RIX4414-
RIX4414-Pl group) or a 0,2 month (RIX4414-Pl-RIX4414
group) schedule, or 3 placebo doses(placebo group). Rou-
tine EPI vaccines were administered concomitantly. Serum
anti-rotavirus IgA concentrations (ELISA,cut-off ≥20U/mL)
were determined at pre-Dose1 and 1 month post-Dose2 of
RIX4414-liq. The anti-rotavirus IgA seroconversion(SC) rates
and corresponding Geometric Mean Concentrations(GMCs)
were calculated. Solicited symptoms were collected 8 days
post-each dose, safety data were collected throughout the
study.
Results: At 1 month post-Dose2 of RIX4414-liq, the
anti-rotavirus IgA SC rate was 63.3%(95%CI:54.3;71.6)
in the RIX4414-RIX4414-Pl group(n = 128) and
81.5%(95%CI:73.4;88.0) in the RIX4414-Pl-RIX4414
group(n = 119). The SC rate observed in the placebo group
at the same time points was 7.8%(95%CI:2.6;17.3)(n = 64)
and 15.4%(95%CI:7.6;26.5)(n = 65). Corresponding anti-
rotavirus IgA GMCs for seropositive infants were
253.8U/mL(95%CI:184.8;348.7) in the RIX4414-RIX4414-Pl
group and 338.0U/mL(95%CI:248.2;460.4) in the RIX4414-
Pl-RIX4414 group. There was no evidence of difference
between the RIX4414-liq groups and the placebo group for
serious adverse events, and for reported solicited events.
Conclusion: This study demonstrates that two doses of
RIX4414 (RotarixTM) oral suspension(liquid formulation) co-
administered with routine EPI vaccines in two different
schedules elicit a high immunogenicity response in Viet-
namese children. Seroconversion rates in this setting are in
line with seroconversion rates observed in a large phaseIII
Latin-America study where high efﬁcacy (85%) was observed
against severe RVGE.
doi:10.1016/j.ijid.2008.05.366
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Background: RIX4414(Rotarix, a trademark of Glax-
oSmithKline), an oral live attenuated human rotavirus
(RV) vaccine has previously been shown to be highly
effective against RV gastroenteritis(GE). The efﬁcacy
evaluation of RIX4414 administered concomitantly with
